ES2145142T3 - Compuesto de acido succinamico, procedimiento para su produccion y su uso. - Google Patents
Compuesto de acido succinamico, procedimiento para su produccion y su uso.Info
- Publication number
- ES2145142T3 ES2145142T3 ES94921848T ES94921848T ES2145142T3 ES 2145142 T3 ES2145142 T3 ES 2145142T3 ES 94921848 T ES94921848 T ES 94921848T ES 94921848 T ES94921848 T ES 94921848T ES 2145142 T3 ES2145142 T3 ES 2145142T3
- Authority
- ES
- Spain
- Prior art keywords
- succinamic acid
- pharmaceutically acceptable
- acceptable salt
- acid compound
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE PRESENTA UN COMPUESTO DE ACIDO SUCCINAMICO DE LA FORMULA (I) EN DONDE R1 ES ALQUILO O ALQUENILO INFERIOR Y R2 ES UN CARBOXILO OPCIONALMENTE ESTERIFICADO, TAMBIEN SE PRESENTA UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL COMPUESTO, UN AGENTE PARA LA PROFILAXIS Y/O EL TRATAMIENTO DE LAS COMPLICACIONES DE LA DIABETES, QUE COMPRENDE, COMO INGREDIENTE ACTIVO, EL COMPUESTO DE ACIDO SUCCINAMICO O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO, UN INHIBIDOR DE LA REDUCTASA DE ALDOSA, QUE COMPRENDE, COMO INGREDIENTE ACTIVO EL COMPUESTO DE ACIDO SUCCINAMICO O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO, Y UN METODO PARA PRODUCIR EL COMPUESTO DE ACIDO SUCCINAMICO O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO. LOS NUEVOS COMPUESTOS DEL ACIDO SUCCINAMICO DE LA FORMULA (I) DE LA INVENCION Y LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS TIENEN UNA POTENTE ACTIVIDAD INHIBIDORA DE LA REDUCTASA DE ALDOSA EN MAMIFEROS TALES COMO LOS HUMANOS, Y MUESTRAN UNA SUPERIOR SEGURIDAD. POR LO TANTO, SON UTILES COMO AGENTES FARMACOLOGICOS PARA EL TRATAMIENTO DE LAS COMPLICACIONES DE LA DIABETES TALES COMO LA UNION DEFECTUOSA DE LESIONES CORNEALES, LAS CATARATAS, LA NEUROSIS, LA RINOPATIA Y LA NEFROPATIA, EN PARTICULAR, LAS CATARATAS Y LA NEUROSIS. DE ACUERDO CON EL METODO DE PRODUCCION DE LA INVENCION, SE SUMINISTRA UN METODO EFICIENTE DE PRODUCCION DE TALES COMPUESTOS DE LA INVENCION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5250925A JPH0782259A (ja) | 1993-09-14 | 1993-09-14 | スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2145142T3 true ES2145142T3 (es) | 2000-07-01 |
Family
ID=17215069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94921848T Expired - Lifetime ES2145142T3 (es) | 1993-09-14 | 1994-08-01 | Compuesto de acido succinamico, procedimiento para su produccion y su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5688818A (es) |
| EP (1) | EP0719767B1 (es) |
| JP (1) | JPH0782259A (es) |
| KR (1) | KR960704870A (es) |
| CN (1) | CN1134699A (es) |
| AT (1) | ATE192442T1 (es) |
| AU (1) | AU680670B2 (es) |
| CA (1) | CA2171756A1 (es) |
| DE (1) | DE69424295T2 (es) |
| ES (1) | ES2145142T3 (es) |
| TW (1) | TW324719B (es) |
| WO (1) | WO1995007898A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2184499A (en) | 1998-01-30 | 1999-08-16 | R-Tech Ueno, Ltd. | Ophthalmic composition |
| WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
| TWI266901B (en) | 2005-12-26 | 2006-11-21 | Au Optronics Corp | Color filter and method for fabricating the same |
| WO2020064174A1 (en) * | 2018-09-25 | 2020-04-02 | Antabio Sas | Indane derivatives for use in the treatment of bacterial infection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822809A (en) * | 1987-11-13 | 1989-04-18 | Abbott Laboratories | Benzazole lipoxygenase inhibiting compounds |
| JP3126541B2 (ja) * | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
-
1993
- 1993-09-14 JP JP5250925A patent/JPH0782259A/ja active Pending
-
1994
- 1994-08-01 ES ES94921848T patent/ES2145142T3/es not_active Expired - Lifetime
- 1994-08-01 KR KR1019960701236A patent/KR960704870A/ko not_active Application Discontinuation
- 1994-08-01 US US08/617,824 patent/US5688818A/en not_active Expired - Fee Related
- 1994-08-01 WO PCT/JP1994/001266 patent/WO1995007898A1/ja active IP Right Grant
- 1994-08-01 CA CA002171756A patent/CA2171756A1/en not_active Abandoned
- 1994-08-01 DE DE69424295T patent/DE69424295T2/de not_active Expired - Fee Related
- 1994-08-01 CN CN94194057A patent/CN1134699A/zh active Pending
- 1994-08-01 AU AU72389/94A patent/AU680670B2/en not_active Ceased
- 1994-08-01 AT AT94921848T patent/ATE192442T1/de not_active IP Right Cessation
- 1994-08-01 EP EP94921848A patent/EP0719767B1/en not_active Expired - Lifetime
- 1994-08-03 TW TW083107087A patent/TW324719B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| DE69424295T2 (de) | 2000-10-26 |
| AU680670B2 (en) | 1997-08-07 |
| US5688818A (en) | 1997-11-18 |
| ATE192442T1 (de) | 2000-05-15 |
| DE69424295D1 (de) | 2000-06-08 |
| AU7238994A (en) | 1995-04-03 |
| EP0719767B1 (en) | 2000-05-03 |
| KR960704870A (ko) | 1996-10-09 |
| JPH0782259A (ja) | 1995-03-28 |
| EP0719767A4 (en) | 1997-01-08 |
| EP0719767A1 (en) | 1996-07-03 |
| CA2171756A1 (en) | 1995-03-23 |
| TW324719B (en) | 1998-01-11 |
| WO1995007898A1 (fr) | 1995-03-23 |
| CN1134699A (zh) | 1996-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2082805T3 (es) | Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos. | |
| ATE223378T1 (de) | Prolineamid-derivate | |
| ES476496A1 (es) | Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. | |
| NO904202L (no) | Terapeutisk aktive bifenylmetanderivater og fremgangsmaatefor deres fremstilling. | |
| DE69320405D1 (de) | Ophthalmische Zusammensetzungen enthaltend als Wirkstoff Vitamin-E oder Ester davon | |
| ES538847A0 (es) | Un derivado de fenilserina | |
| ID27509A (id) | Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya | |
| ES2145142T3 (es) | Compuesto de acido succinamico, procedimiento para su produccion y su uso. | |
| DE69512208D1 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
| CA2202904A1 (en) | Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases | |
| ES2132394T3 (es) | Compuesto de benzotiazol, procedimiento para su produccion, y su utilizacion. | |
| EP0644194A4 (en) | COMPOUND BASED ON PYRIDOTHIAZINEACETIC ACID, PROCESS FOR PRODUCTION AND USE. | |
| AU7424394A (en) | 3- or 4-glycosyloxybenzopyran derivatives and antiallergic agents containing the derivatives as active ingredients | |
| ES2130403T3 (es) | Derivado del acido quinolin-3-acetico, procedimiento para su produccion, y uso del mismo. | |
| ATE235900T1 (de) | Hemmer der subepithelialen turbidität | |
| EP0738727A4 (en) | 1,4-BENZOXAZINE-2-ACETIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | |
| DE69532963D1 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen | |
| ES2061579T3 (es) | Compuestos cefem y procedimientos para su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 719767 Country of ref document: ES |